Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials
-
- Sakai
- 作成者
収録刊行物
-
- Clin Ther
-
Clin Ther 38 (843–62), e9-, 2016